MEPACT 4mg (mifamurtide): Potential for filter leakage or malfunction

Dear Healthcare Professional,

Takeda France SAS, in agreement with the European Medicines Agency and the <National Competent Authority> would like to inform you of the following:

Summary:

- **Mepact is available as a vial containing a powder for reconstitution and one single-use filter.**
- **A small number of filter leakages or of malfunction during reconstitution of Mepact have been reported. They occur before Mepact is infused.**
- **To protect patients, if any leakage or malfunction of the filter are observed during reconstitution, do not administer Mepact and report the malfunction to Takeda.**
- **A new Mepact package (vial and filter) must be used.**
- **Mepact must only be reconstituted using the filter provided in the package.**

Background on the safety concern:

Mepact is indicated in children, adolescents and young adults for treating high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with post-operative multi-agent chemotherapy.

Mepact is available as a vial containing a powder for reconstitution and one single-use filter. Mepact must only be reconstituted using the filter provided in the package; the vented spike filter ensures the uniformity of size of liposomes before infusion.

Healthcare professionals have reported a small number of instances of filter leakage or malfunction during reconstitution of Mepact. This occurs before Mepact is infused. Filters showed no visible defect prior to usage.

To safeguard patient safety and to ensure the correct concentration during reconstitution, if you observe any leakage or malfunction of the filter during reconstitution, do not administer Mepact and report the malfunction to Takeda <Takeda LOC information to be inserted>. A new Mepact package (vial and filter) must be used.

Takeda is currently working with the filter manufacturer on the investigation to help identify the probable root cause for the complaints received specific to the Mepact Spike Filters. Appropriate corrective actions will be identified and implemented to mitigate against future issues with the Mepact Spike Filters. Target completion of the investigation is end of March 2020.

For questions on the content of this communication please contact Takeda Medical Information Department: Tel: <Takeda LOC information to be inserted>. Email: <Takeda LOC information to be inserted>.

Yours faithfully,

Medical Director
<Qualified Person for Pharmacovigilance or Regional Equivalent>
<Name> <Name>
<Title> <Regional e.g. UK>

DHPC COMMUNICATION PLAN	
Medicinal product(s)/active substance(s)	Mepact 4mg (mifamurtide)
Marketing authorisation holder(s)	Takeda France SAS
Safety concern and purpose of the communication	Potential for filter leakage / malfunction
DHPC recipients	Oncologists responsible for treating osteosarcoma patients. Hospital pharmacists responsible for handling Mepact
Member States where the DHPC will be distributed	Austria, Cyprus, Czech Republic, Estonia, France, Germany, Greece, Ireland, Italy, Slovakia, Spain, plus Norway, United Kingdom

Timetable	Date
DHPC and communication plan (in English) agreed by CHMP/CMDh	18th February 2020
Submission of translated DHPCs to the national competent authorities for review	20th February 2020
Agreement of translations by national competent authorities	24th February 2020
Dissemination of DHPC	25th – 28th February 2020